Tolerability Profile of Cosibelimab in Advanced Cutaneous Squamous Cell Carcinoma

With efficacy across the approved checkpoint inhibitors largely comparable, the faculty turn to tolerability as a differentiating factor and examine cosibelimab in detail. Dr In describes the recurring observation across clinical trial datasets of a lower incidence of immune-related adverse events with cosibelimab, including the absence of grade 4 and grade 5 immune-related events in the pivotal study. The faculty discuss the leading mechanistic hypothesis, namely that selective PD-L1 blockade preserves PD-L2 signaling in a way that PD-1 blockade does not, potentially reducing off-target immune activation. Dr In explains how this tolerability profile has influenced his own selection in frail and heavily comorbid patients for whom a serious immune-related toxicity would be difficult to manage. The faculty also note planned and ongoing studies evaluating the agent in populations historically excluded from immunotherapy trials, including patients with autoimmune disease and solid organ transplant recipients.